Title: Reduction in cardiovascular death with empagliflozin is consistent across categories of baseline HbA1c and change in HbA1c: Results from EMPA-REG OUTCOME
Abstract: In the EMPA-REG OUTCOME trial, empagliflozin given in addition to standard of care significantly reduced cardiovascular (CV) death vs. placebo (HR 0.62; 95% CI 0.49, 0.77) in patients with type 2 diabetes (T2DM) and established CV disease. We investigated whether baseline HbA1c or change in HbA1c influenced the effect of empagliflozin on CV death.
Publication Year: 2018
Publication Date: 2018-04-01
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
Cited By Count: 5
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot